Zemaira: payments to doctors
Payments that named Zemaira as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $482K
- Providers
- 1,885
- Transactions
- 3,875
- Average per transaction
- $124
The per-transaction average — $124 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,885 providers the average total is $256, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| CSL Behring | $415,894 | 86.3% |
| Vifor Pharma, Inc. | $66,116 | 13.7% |